55 Randomized phase II clinical trial of cetuximab in combination with cisplatin (C) and vinorelbine (V) or CV alone in patients with advanced epidermal growth factor receptor (EGFR)-expressing non-small-cell lung cancer (NSCLC)

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

55 Randomized phase II clinical trial of cetuximab in combination with cisplatin (C) and vinorelbine (V) or CV alone in patients with advanced epidermal growth factor receptor (EGFR)-expressing non-small-cell lung cancer (NSCLC)

Cited by 3 publications

References 0 publications

Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer

Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer

2003 Highlights From: XII European Cancer Conference Copenhagen, Denmark September 21-25, 2003

Anti—Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab Plus Doxorubicin in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Contact Info

Product

Resources

About